In prostate cancer cells LNCaP and DuPro, genistein treatment led to significant chromatin remodeling, characterized by an enrichment of H3ac, H4ac, and H3K4me2, near the transcription start sites of p16 and p21. The gene discussed is CDKN1A; the disease is prostate cancer.